Integral Molecular, the industry leader in the discovery and engineering of antibodies against membrane proteins, announces ...

The bispecific antibodies market presents growth opportunities in cancer, autoimmune, and inflammatory therapies, driven by robust clinical progress, technological innovation, and strategic ...

Artists Earn a $1,000 Stipend While Inspiring Drug DiscoveryMADISON, Wis.--(BUSINESS WIRE)--Invenra, Inc., a biotechnology company pioneering multispecific antibody therapeutics, is requesting cancer ...

The open-label, multi-center Phase Ⅱ clinical study is led by Professor Shen Lin of Beijing Cancer Hospital and is being conducted across multiple hospitals in China. The trial aims to evaluate the ...

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can ...

UAB researchers discover that the immune system consistently targets the same region of mismatched HLA proteins after organ ...

In the race of innovative drug R&D, whether for antibodies, peptides, or novel binding proteins, the efficiency of early-stage molecule discovery is always the key factor determining project success ...

Study details the development of a novel antibody that targets a specific type of B7-H3, a protein overexpressed in many cancers This antibody technology was used to create BetaBart, an ...

Longhorn Vaccines and Diagnostics (LHNVD), an IND enabling-stage biopharmaceutical company, today announced it will present new preclinical data demonstrating that DRG5--BD11, a novel human bispecific ...

First-in-human study of EPI-326 will evaluate the company's lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential to expand to CRC AACR 2026 presentations, including New ...

The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an ...